Results 41 to 50 of about 5,569,467 (288)

Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family

Frontiers in Immunology, 2016
The interleukin (IL)-6/IL-12 family cytokines have pleiotropic functions and play critical roles in multiple immune responses. This cytokine family has very unique characteristics in that they are composed of two distinct subunits forming a heterodimer ...
Hideaki Hasegawa, Izuru Mizoguchi, Yukino Chiba, Mio Ohashi, Mingli Xu, Takayuki Yoshimoto   +5 more
doaj   +1 more source

IL-23 stabilizes an effector Treg cell program in the tumor microenvironment

Nature Immunology
Interleukin-23 (IL-23) is a proinflammatory cytokine mainly produced by myeloid cells that promotes tumor growth in various preclinical cancer models and correlates with adverse outcomes. However, as to how IL-23 fuels tumor growth is unclear.
Tobias Wertheimer, P. Zwicky, Lukas Rindlisbacher, Colin Sparano, Marijne Vermeer, Bruno Marcel Silva de Melo, C. Haftmann, T. Rückert, A. Sethi, S. Schärli, Anna Huber, F. Ingelfinger, Caroline Xu, Daehong Kim, Philipp Häne, André Fonseca da Silva, A. Muschaweckh, Nicolas Nunez, Sinduya Krishnarajah, Natalie Köhler, R. Zeiser, M. Oukka, Thomas Korn, Sonia Tugues, Burkard Becher   +24 more
semanticscholar   +1 more source

Prevalence of 21 Physician‐Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier, Brittany Grantham, Camilla Grud Nielsen, Louise Lundgren, Liv Andrés‐Jensen, Kjeld Schmiegelow, Chris Selman, Gareth Ball, Elyse Passmore, David A. Elliott, Rachel Conyers   +10 more
wiley   +1 more source

Biologic Treatments of Psoriasis: An Update for the Clinician

Biologics: Targets & Therapy, 2021
Nicholas D Brownstone, Julie Hong, Megan Mosca, Edward Hadeler, Wilson Liao, Tina Bhutani, John Koo University of California, San Francisco, Department of Dermatology, Psoriasis and Skin Treatment Center, San Francisco, CA, USACorrespondence: Nicholas D ...
Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J   +6 more
doaj  

Incidence and Severity of Carboplatin‐Associated Hearing Loss in Children With Cancer Assessed by the SIOP Boston 2012 Ototoxicity Criteria

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla, Sean Carter, Andrew Wood, Sandra Staffieri, Andrew Dodgshun, David D. Eisenstat, Michael Sullivan   +6 more
wiley   +1 more source

IL-23 promotes TCR-mediated negative selection of thymocytes through the upregulation of IL-23 receptor and RORγt [PDF]

Nature Communications, 2014
Transient thymic involution is frequently found during inflammation, yet the mode of action of inflammatory cytokines is not well defined. Here we report that interleukin-23 (IL-23) production by the thymic dendritic cells (DCs) promotes apoptosis of the CD4(hi)CD8(hi) double-positive (DP) thymocytes.
Li, Hao, Hsu, Hui-Chen, Wu, Qi, Yang, PingAr, Li, Jun, Luo, Bao, Oukka, Mohamed, Steele, Claude H., Cua, Daniel J, Grizzle, William E., Mountz, John D.   +10 more
openaire   +2 more sources

Effect of Epigallocatechin gallate (EGCG) on Production of Dendritic Cells from Peripheral Blood Monocytes

Journal of Mazandaran University of Medical Sciences, 2020
Background and purpose: Dendritic cells are professional antigen presenting cells that initiate and modulate immune responses. Epigallocatechin gallate (EGCG) is identified as a prophylactic agent that can suppress tumor formation. This research aimed at
Mohammad Ali Mofid Nakhaei, Nabiallah Mohammadi, Saeid Abediankenari   +2 more
doaj  

Guselkumab binding to CD64⁺ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. [PDF]

Front Immunol
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue. Our complementary analyses of transcriptomic datasets from psoriasis and IBD showed increased expression of ...
Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, Manieri NA, Bao P, Greving C, Lacy ER, DuPrie M, Wertheimer J, Deming JD, Brown J, Hart A, Li HH, Freeman TC, Keyes B, Kohler K, White I, Karpowich N, Steele R, Elloso MM, Fakharzadeh S, Goyal K, Lavie F, Abreu MT, Allez M, Atreya R, Bissonnette R, Eyerich K, Krueger JG, McGonagle D, McInnes IB, Ritchlin C, Fourie AM.   +35 more
europepmc   +5 more sources

Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases

International Journal of Molecular Sciences, 2019
Innate immunity represents the semi-specific first line of defense and provides the initial host response to tissue injury, trauma, and pathogens. Innate immunity activates the adaptive immunity, and both act highly regulated together to establish and ...
K. Bunte, T. Beikler
semanticscholar   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source